Kidney Cancer Coverage From Every Angle

Recent News

Pegilodecakin Plus Anti–PD-1 Therapy for Renal Cell Carcinoma
ATLAS Trial: Axitinib in Patients at High Risk of Recurrence of Kidney Cancer
Exploring the Mechanism of MTAP Regulation in Renal Cell Carcinoma
Kidney Week 2018: Does Diabetes Increase the Risk for Renal Tumorigenesis?
Breakthrough Therapy Designation Granted by FDA to UGN-101 in Urothelial Cancer
ESMO 2018: Cabozantinib in PD-L1–Unselected Patients With Metastatic Kidney Cancer
ESMO 2018: In Kidney Cancer, Response to Treatment Varies With Gene Expression
ASTRO 2018: Stereotactic Ablative Radiotherapy for Patients With One Kidney
ESMO 2018: Novel First-Line Combination Therapy for Advanced Kidney Cancer
Kidney Week 2018: Shedding Light on Origin of Papillary Kidney Cancer
ASTRO 2018: Toxicity of Stereotactic Body Radiation Therapy in Primary Kidney Cancer
Kidney360: New Journal From the American Society of Nephrology
Treating Oligometastatic Disease: A New Look at Stereotactic Body Radiation Therapy
Updated NCCN Guidelines for Kidney Cancer: Expanded Use of Cabozantinib Featured
Predicting Immunotherapy Response in Clear Cell Kidney Cancer
Novel Approach to Noninvasive Identification of CD117-Positive Kidney Tumors
Novel Blood Test Used to Predict Kidney Cancer Risk and Survival
Single-Cell Transcriptomes Reveal Cellular Identity of Renal Carcinomas
Renal Function After Partial Nephrectomy: To Clamp or Not to Clamp
FDA Updates Prescribing Information for Pembrolizumab and Atezolizumab in Urothelial Cancer
FDA Grants Fast Track Designation to VB4-845 for Treatment of Type of Bladder Cancer
For Early Kidney Cancer, Which Surgical Approach to Partial Nephrectomy Is Best?
Immunosuppressants and Squamous Cell Carcinoma in Renal Transplant Recipients
Does Renal Transplant Rejection Influence Risk of Developing Squamous Cell Carcinoma?
Potential Therapeutic Target Identified in Clear Cell Renal Cell Carcinoma
Delayed Skin Reactions Reported With PD-1 Inhibitors
Percutaneous Ablation as Nonsurgical Alternative for Patients With T1a Kidney Cancer
Does Prior Antibiotic Use Affect Treatment Outcomes in Renal Cell Carcinoma?
Use of Pembrolizumab Before Radical Cystectomy in Urothelial Bladder Cancer
Early Study of Antibody-Drug Conjugate in Urothelial Cancer
Improved Quality of Life With Combination Immunotherapy in Advanced Kidney Cancer
ASCO 2018: Phase II Study Results With Erdafitinib in Metastatic Urothelial Cancer
FDA Restricts Use of Pembrolizumab or Atezolizumab in Some Patients Treated for Urothelial Carcinoma
Does Statin and Sartan Use Affect Outcomes in Patients Treated for Kidney Cancer?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.